CureVac N.V. is an "underappreciated" buying opportunity, according to UBS. Analyst Eliana Merle upgraded shares of the German biotech company to buy from...
Shares of Aclaris Therapeutics can surge more than 60% on the back of a possible new treatment for immuno-inflammatory diseases, including rheumatoid arthritis,...
Copa 's stock could rally as air travel continues to rebound and industry-wide headwinds ease, according to JPMorgan. Analyst Guilherme Mendes upgraded the...